About galectin therapeutics - GALT
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
GALT At a Glance
Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard
Norcross, Georgia 30071
| Phone | 1-678-620-3186 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -30,836,000.00 | |
| Sector | Health Technology | Employees | 9 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GALT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -19.174 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.348 |
GALT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,426,222.222 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GALT Liquidity
| Current Ratio | 2.42 |
| Quick Ratio | 2.42 |
| Cash Ratio | 2.207 |
GALT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -166.56 |
| Return on Equity | N/A |
| Return on Total Capital | -407.776 |
| Return on Invested Capital | N/A |
GALT Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 1,768.805 |
| Total Debt to Total Assets | 684.81 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 1,768.514 |